Dividend Investing Center
Portfolio Strategy Center
ETFs & Funds
This user currently has no profile.
Stephen is the President of Kilmer Lucas Inc. (www.kilmerlucas.com) and BioTuesday Publishing Corporation (www.biotuesday.ca). Prior to founding both firms, he was the VP of Investor & Public Affairs for OccuLogix Inc., a Boston-based medical device company. Before managing OccuLogix’ spin-out on the TSX and NASDAQ via the largest healthcare IPO in Canadian market history and the first successful IPO of a non-FDA-approved medical device company on a major U.S. exchange in more than a decade, he served as the VP of Investor Relations and Corporate Communications for TLC Vision Corporation, the St. Louis-based LASIK eye surgery pioneer and OccuLogix’ parent company.
Stocks - long
BioTuesday Publishing Corporation, a wholly-owned subsidiary of Kilmer Lucas Inc.
With offices in Toronto and San Francisco, Kilmer Lucas is a leading investor relations and corporate communications boutique. We are differentiated in two important ways. First, while we feel equally comfortable navigating the capital markets and media on both sides of the border, we have been especially
effective in leveraging our longstanding relationships and strong track record of success in the U.S. for the benefit of Canadian issuers. Second, in addition to providing a full range of traditional IR and PR services, we have developed particular expertise in IR 2.0 — offering innovative social media strategies, programs and tools that are Reg FD compliant.
One thing is crystal clear – ever since Leonard Zehr retired from The Globe and Mail, there has been a noticeable void of traditional Canadian business media coverage of all but the very largest healthcare issuers. So, we’ve created BioTuesday.ca to change that. Our goal is to give great, but not necessarily
big or well known, healthcare companies and their stories the exposure that they deserve. We plan on covering as many companies as we can. If we call you for an interview, please rest assured that there are truly no strings or costs attached. There also won’t be any outside voices tearing your company apart in our blog posts. Instead, we’ve designed this to be a user-friendly chance for CEOs and other execs to sketch where they are and where they’re going.
Currently, there are no book details for Bio Tuesday.
Tekmira partner starts human trials of ALN-TTR01
Medical Lab division to drive Warnex
TearLab set to join Russell Microcap Index
Dundee upgrades AEterna to Buy
Riding the Next Wave